The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Study to Evaluate Efficacy and Safety of BGB-3111 in Participants With Relapsed or Refractory Mantle Cell Lymphoma (MCL)
Official Title: A Single-Arm, Open-Label, Multicenter Phase 2 Study to Evaluate Efficacy and Safety of BGB-3111, a Bruton's Tyrosine Kinase (BTK) Inhibitor, in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (MCL)
Study ID: NCT03206970
Brief Summary: The primary objective of this study was to evaluate the efficacy of zanubrutinib in participants with centrally confirmed relapsed or refractory MCL.
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Beijing Cancer Hospital, Beijing, Beijing, China
Peking Union Medical College Hospital, Beijing, Beijing, China
Fujian Medical University Union Hospital, Fuzhou, Fujian, China
Nanfang Hospital of Southern Medical University, Guangzhou, Guangdong, China
Henan Cancer Province, Zhengzhou, Henan, China
Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology, Wuhan, Hubei, China
Jiangsu Province Hospital, Nanjing, Jiangsu, China
The First Affiliated Hospital of Jinlin University, Chang chun, Jilin, China
Fudan University Cancer Center, Shanghai, Shanghai, China
West China Hospital, Sichuan University, Chengdu, Sichuan, China
Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin, Tianjin, China
Tianjin Cancer Hospital, Tianjin, Tianjin, China
The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, China
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
Name: Study Director
Affiliation: BeiGene
Role: PRINCIPAL_INVESTIGATOR